cp wire

CP Wire Articles

Clovis Starts Ph III Trial with Combination of Rubraca and Opdivo in Advanced Ovarian Cancer



Clovis Oncology, Inc. (NASDAQ: CLVS) announced on 8/8/18 the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca (rucaparib), a... read more

Wed, 08/8/18 - 09:01 am
How Companies Protect Intellectual Property Involving Live Microbes - Interview With a Patent Attorney



With so many companies developing products related to the microbiome that include live microbes, we were curious about how companies are protecting their intellectual property. Since some... read more

Tue, 08/7/18 - 10:59 am
SBIR Awards $2.3 Million Grant to Agilvax to Advance Immunotherapy for Triple Negative Breast Cancer

Agilvax, Inc. announced on 8/7/18 the receipt of a Fast Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). The grant will provide up to $2.3 million in... read more

Tue, 08/7/18 - 09:59 am
China Approves Gilead's Genvoya for HIV-1 Infection
  • Genvoya is the first TAF-based single tablet regimen for the treatment of HIV to be approved in China
  • There were approximately 140,000 people newly diagnosed with HIV in China as of... read more
Mon, 08/6/18 - 09:35 am
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
  • Clinical data expected in 2019
  • HPN424 is designed as an ‘off-the-shelf’ T cell therapy
  • HPN424 serum half-life of 80 hours supporting once-weekly administration
... read more
Mon, 08/6/18 - 09:20 am

Pages